Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
04/08/2025 22:00
Syndax Pharmaceuticals Inc SNDX.OQ reported a quarterly adjusted loss of 83 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -80 cents. The mean expectation of fourteen analysts for the quarter was for a loss of $1.02 per share. Wall Street expected results to range from $-1.12 to -92 cents per share. Revenue rose 984.5% to $37.96 million from a year ago; analysts expected $26.82 million. Syndax Pharmaceuticals Inc's reported EPS for the quarter was a loss of 83 cents. The company reported a quarterly loss of $71.85 million. Syndax Pharmaceuticals Inc shares had risen by 6.6% this quarter and lost 24.5% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 4.8% in the last three months. In the last 30 days, two analysts negatively revised earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Syndax Pharmaceuticals Inc is $33.50, about 70.2% above its last closing price of $9.98 This summary was machine generated from LSEG data August 4 at 09:00 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -1.02 | -0.83 | Beat |
| Mar. 31 2025 | -1.33 | -0.98 | Beat |
| Dec. 31 2024 | -0.23 | -1.10 | Missed |
| Sep. 30 2024 | -1.11 | -0.98 | Beat |
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million